"Three-Dimensional MRI Analysis of Paraspinal Muscle Volume Following Radiofrequency Neurotomy in Chronic Lumbar Facet Syndrome: The Modulating Role of Exercise"
Chronic lumbar facet syndrome is an important cause of persistent low back pain and functional limitation. Lumbar medial branch radiofrequency neurotomy (RFN) is a minimally invasive treatment used in patients with facet-mediated pain confirmed by diagnostic medial branch blocks. However, because the medial branch nerves also provide motor innervation to the multifidus muscle, the potential long-term effects of RFN on paraspinal muscle volume remain uncertain.
This prospective, randomized controlled trial aims to investigate changes in multifidus and erector spinae muscle volume following conventional lumbar medial branch RFN and to evaluate whether a home-based core stabilization exercise program influences these changes.
A total of 26 patients with chronic lumbar facet syndrome will be enrolled following a positive response, defined as at least a 50% reduction in pain intensity, to fluoroscopy-guided diagnostic lumbar medial branch block. All participants will undergo conventional lumbar medial branch RFN under fluoroscopic guidance. Following RFN, participants will be randomly assigned in a 1:1 ratio to either an RFN plus exercise group or an RFN-only group. The exercise group will receive a six-week home-based core stabilization exercise program, with adherence monitored through weekly telephone calls.
Magnetic resonance imaging (MRI) will be used to assess multifidus and erector spinae muscle volumes before RFN and at 12 months after treatment. MRI images will be analyzed using deep learning-based automatic segmentation and computer-assisted three-dimensional volumetric analysis, with muscle volumes calculated using voxel-based methods.
Pain intensity, lumbar range of motion, functional disability, health-related quality of life, neurological examination findings, and analgesic use will be assessed at baseline and at 1, 3, 6, and 12 months after RFN. The study will evaluate changes in paraspinal muscle volume following RFN and the potential contribution of core stabilization exercises to muscle volume preservation and clinical outcomes.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Background and Study Objectives Chronic lumbar facet syndrome is an important cause of persistent axial low back pain and functional disability. Lumbar medial branch radiofrequency neurotomy (RFN) is a minimally invasive treatment option for patients with suspected facet-mediated pain who demonstrate a positive response to diagnostic medial branch blocks. However, because the lumbar medial branch nerves also provide motor innervation to the multifidus muscle, RFN may affect paraspinal muscle morphology and function. The long-term effects of RFN on multifidus and erector spinae muscle volume remain uncertain.
In this study, deep learning-based three-dimensional MRI volumetric analysis will be used to assess paraspinal muscle volume. This advanced approach enables more comprehensive volumetric assessment and may reduce measurement errors and observer-related variability compared with conventional methods.
The primary objective of this prospective, randomized controlled trial is to evaluate changes in multifidus and erector spinae muscle volume following conventional lumbar medial branch RFN using magnetic resonance imaging (MRI) and deep learning-based three-dimensional volumetric analysis. The study will also investigate whether a six-week home-based core stabilization exercise program influences paraspinal muscle volume changes and clinical outcomes after RFN.
Study Population and Diagnostic Medial Branch Block A total of 26 patients aged 50-70 years with chronic axial low back pain and suspected lumbar facet syndrome will be enrolled after demonstrating a positive response to a diagnostic lumbar medial branch block.
Diagnostic medial branch blocks will be performed under fluoroscopic guidance with patients in the prone position. Target levels will be selected according to physical examination findings, areas of tenderness, lumbar MRI findings, and the anatomical innervation of the suspected painful facet joints. Unilateral or bilateral procedures will be performed according to the distribution of symptoms.
Following sterile preparation, local skin anesthesia will be administered using 2 mL of 1% lidocaine before needle insertion.
Needle placement near the junction of the superior articular process and transverse process, or at the appropriate anatomical target for the L5 dorsal ramus, will be confirmed using oblique, anteroposterior, and lateral fluoroscopic views.
Before administration of the diagnostic local anesthetic, 0.5 mL of radiopaque contrast medium will be injected under real-time fluoroscopy to exclude vascular uptake. Subsequently, 0.5 mL of 2% lidocaine will be injected at each target level.
Pain intensity will be assessed using the Visual Analog Scale (VAS) before the block and at 0, 2, 4, 6, and 8 hours after the procedure. Patients demonstrating at least a 50% reduction in pain intensity following the diagnostic block will be considered eligible for RFN and study enrollment. The diagnostic block is used to support the selection of patients with suspected facet-mediated pain for RFN.
Radiofrequency Neurotomy Procedure All enrolled participants will undergo conventional lumbar medial branch RFN under fluoroscopic guidance using standardized procedural parameters.
Before the procedure, heart rate, blood pressure, and oxygen saturation will be monitored. RFN will be performed with the patient in the prone position under sterile conditions. Following sterile preparation, 2 mL of 1% lidocaine will be administered for local skin anesthesia before RF cannula insertion.
A 20-gauge radiofrequency cannula with a 10-mm active tip (Abbott Medical, USA) will be advanced under ipsilateral oblique C-arm fluoroscopic guidance, with the cannula oriented parallel to the course of the target medial branch nerve. The cannula will be positioned in contact with bone near the junction of the superior articular process and transverse process. For the L5 dorsal ramus, the cannula will be positioned in the groove between the sacral ala and the superior articular process of S1.
Before lesioning, sensory stimulation will be performed at 50 Hz, aiming to elicit a sensory response at 0.5 V or less. Motor stimulation will then be performed at 2 Hz to confirm multifidus muscle contraction without lower-extremity muscle contraction.
Using a conventional radiofrequency generator (NeuroTherm NT1100, Neurotherm Inc., USA), thermal lesions will be created at 70°C for 90 seconds at each target nerve.
At the end of the procedure, 1 mL of 2% lidocaine will be injected through each cannula.
Participants will be observed for 30 minutes after RFN to monitor for potential complications and will be discharged if clinically stable.
Randomization and Exercise Intervention Following RFN, participants will be randomly assigned in a 1:1 ratio using a computer-generated randomization schedule to one of two groups, with 13 participants planned for each group.
Group 1 - RFN Plus Exercise: Participants will receive a six-week home-based core stabilization exercise program in addition to RFN. Exercises will be taught by a physiotherapist and will focus on lumbar core stabilization, including activation and strengthening of the lumbar stabilizing musculature. Adherence to the home exercise program will be assessed and documented through weekly telephone calls. Core stabilization exercises have been investigated for their effects on pain-related outcomes and lumbar muscle characteristics in patients with low back pain.
Group 2 - RFN Alone: Participants will undergo conventional lumbar medial branch RFN without receiving a study-specific core stabilization exercise program.
The RFN procedure and its technical parameters will be the same in both groups. MRI Assessment and Deep Learning-Based Volumetric Analysis Multifidus and erector spinae muscle volumes will be evaluated using lumbar MRI performed before RFN and at the 12-month follow-up.
MRI datasets in Digital Imaging and Communications in Medicine (DICOM) format will be processed using deep learning-based automatic segmentation. The multifidus and erector spinae muscles will be identified and segmented to generate muscle masks for quantitative volumetric assessment.
Spatial metadata from the DICOM images, including pixel spacing, slice thickness, and image position, will be used for voxel-based volume calculations. Rather than relying solely on two-dimensional cross-sectional measurements, the segmented MRI datasets will be evaluated using computer-assisted three-dimensional volumetric analysis. Muscle volumes will be expressed in cubic millimeters (mm³).
Baseline and 12-month muscle volumes will be compared to assess longitudinal changes in the multifidus and erector spinae muscles. Previous MRI-based investigations of paraspinal muscle changes following RFN provide a rationale for quantitative muscle assessment.
The imaging analysis will be performed by an engineer experienced in medical image processing who will be unaware of the spinal segments treated with RFN, as specified in the study protocol.
Clinical Outcome Assessments and Follow-Up Clinical evaluations will be performed before RFN (baseline) and at 1, 3, 6, and 12 months after treatment.
Primary outcome measures will include:
- Changes in multifidus and erector spinae muscle volume between baseline and 12 months, assessed using MRI and deep learning-based volumetric analysis.
- Changes in pain intensity measured using the VAS at rest, during movement, and at night.
Secondary outcome measures will include:
- Lumbar range of motion.
- Functional disability assessed using the Oswestry Disability Index (ODI).
- Health-related quality of life assessed using the Nottingham Health Profile (NHP).
- Neurological examination findings, including sensory function, motor strength, and deep tendon reflexes.
- Analgesic use during follow-up. Clinical outcome measures will be evaluated at baseline and at 1, 3, 6, and 12 months after RFN. MRI-based muscle volume measurements will be obtained at baseline and 12 months.
Study Significance This study will investigate longitudinal changes in multifidus and erector spinae muscle volume following conventional lumbar medial branch RFN using MRI and deep learning-based three-dimensional volumetric analysis.
Because all participants will receive RFN, the randomized comparison will specifically evaluate the additional effect of a six-week home-based core stabilization exercise program on muscle volume changes and clinical outcomes. The findings may help clarify the relationship between post-RFN paraspinal muscle changes, exercise rehabilitation, and patient-reported outcomes over a 12-month follow-up period.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: MUHAMMED FURKAN DAĞ
- Phone Number: +90 507 415 76 97
- Email: furkanduzce.38@gmail.com
Study Contact Backup
- Name: Bilge ÖZLEMİŞ, Prof. Dr.
Study Locations
-
-
-
Ankara, Turkey (Türkiye)
- Recruiting
- Ankara Bilkent City Hospital
-
Contact:
- MUHAMMED FURKAN DAĞ
- Phone Number: +90 507 415 76 97
- Email: furkanduzce.38@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adults aged 50 to 70 years.
- Mechanical low back pain lasting more than 3 months.
- A Visual Analog Scale (VAS) score ≥5 at baseline.
- At least a 50% reduction in the Visual Analog Scale (VAS) score following fluoroscopy-guided diagnostic lumbar medial branch block.
- Ability and willingness to provide written informed consent and comply with the study protocol.
Exclusion Criteria:
- Pregnancy.
- Presence of implanted electronic devices, including a neurostimulator or cardiac pacemaker.
- Diagnosis of an inflammatory rheumatic disease.
- Polyneuropathy that may interfere with treatment or outcome assessment.
- Active malignancy, a history of malignancy within the previous year, or current chemotherapy and/or radiotherapy.
- Severe psychiatric disorders.
- Severe coagulation disorders.
- Active infection.
- Skin disease at the intervention site.
- Lumbar steroid injection and/or physical therapy for low back pain within the previous 3 months.
- Uncontrolled or severe cardiovascular or metabolic disease.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Lumbar Medial Branch Radiofrequency Neurotomy + Home-Based Core Stabilization Exercise Program
Patients with chronic lumbar facet syndrome receiving conventional lumbar medial branch radiofrequency neurotomy followed by a standardized six-week home-based core stabilization exercise program. |
Conventional lumbar medial branch radiofrequency neurotomy will be performed under fluoroscopic guidance using standard clinical techniques for the treatment of chronic lumbar facet syndrome. |
|
Active Comparator: Lumbar Medial Branch Radiofrequency Neurotomy
Patients with chronic lumbar facet syndrome receiving conventional lumbar medial branch radiofrequency neurotomy without an additional exercise program. |
Conventional lumbar medial branch radiofrequency neurotomy will be performed under fluoroscopic guidance using standard clinical techniques for the treatment of chronic lumbar facet syndrome. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Paraspinal Muscle Volume
Time Frame: Baseline and 12 months
|
Change in multifidus and erector spinae muscle volumes (mm³) from baseline to 12 months following radiofrequency neurotomy, assessed using MRI and deep learning-based automatic segmentation with computer-assisted three-dimensional volumetric analysis. |
Baseline and 12 months
|
|
Pain Intensity (Visual Analog Scale, VAS)
Time Frame: Baseline, 1 month, 3 months, 6 months, and 12 months
|
Change in pain intensity assessed using the Visual Analog Scale (VAS; 0-10) for pain at rest, during movement, and at night. Change in pain intensity assessed using the Visual Analog Scale (VAS; 0-10) for pain at rest, during movement, and at night. A score of 0 indicates no pain, and a score of 10 indicates the worst imaginable pain. Higher scores indicate greater pain intensity. |
Baseline, 1 month, 3 months, 6 months, and 12 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Lumbar Range of Motion Measured Using a Goniometer (Degrees)
Time Frame: Baseline, 1 month, 3 months, 6 months, and 12 months
|
Change in lumbar flexion, extension, and right and left lateral flexion range of motion, measured using a goniometer and expressed in degrees (°). Each movement will be assessed separately. |
Baseline, 1 month, 3 months, 6 months, and 12 months
|
|
Oswestry Disability Index (ODI)
Time Frame: Baseline, 1 month, 3 months, 6 months, and 12 months
|
Change in disability assessed using the Oswestry Disability Index (ODI), Version 2.0. Scores are calculated as percentages ranging from 0% (no disability) to 100% (maximum disability). Higher scores indicate greater functional disability. |
Baseline, 1 month, 3 months, 6 months, and 12 months
|
|
Nottingham Health Profile (NHP)
Time Frame: Baseline, 1 month, 3 months, 6 months, and 12 months
|
Change in health-related quality of life assessed using the Nottingham Health Profile (NHP), consisting of 38 yes/no items across six domains: energy, pain, emotional reactions, sleep, social isolation, and physical mobility. Each domain is scored separately using weighted scoring from 0 (no problems) to 100 (maximum problems). Higher scores indicate poorer health-related quality of life. |
Baseline, 1 month, 3 months, 6 months, and 12 months
|
|
Analgesic Consumption
Time Frame: Baseline, 1 month, 3 months, 6 months, and 12 months
|
Change in the type and frequency of analgesic use, including nonsteroidal anti-inflammatory drugs (NSAIDs), paracetamol, and opioid analgesics. |
Baseline, 1 month, 3 months, 6 months, and 12 months
|
|
Change in Lower Extremity Sensory Examination Findings
Time Frame: Baseline, 1 month, 3 months, 6 months, and 12 months
|
Change in lower extremity sensory function assessed by clinical sensory examination and classified into three categories: normal sensation, hypoesthesia (decreased sensation), and hyperesthesia (increased sensation). Sensory function will be evaluated on the treated side in patients undergoing unilateral radiofrequency neurotomy (RFN) and bilaterally in patients undergoing bilateral RFN. |
Baseline, 1 month, 3 months, 6 months, and 12 months
|
|
Change in Lower Extremity Muscle Strength (MRC Scale, 0-5)
Time Frame: Baseline, 1 month, 3 months, 6 months, and 12 months
|
Change in lower extremity muscle strength assessed using manual muscle testing and graded according to the Medical Research Council (MRC) scale, ranging from 0 (no muscle contraction) to 5 (normal muscle strength). Muscle strength will be assessed on the treated side in patients undergoing unilateral RFN and bilaterally in patients undergoing bilateral RFN. |
Baseline, 1 month, 3 months, 6 months, and 12 months
|
|
Change in Lower Extremity Deep Tendon Reflex Classification
Time Frame: Baseline, 1 month, 3 months, 6 months, and 12 months
|
Change in patellar and Achilles deep tendon reflex findings assessed using a reflex hammer and classified into three categories: hypoactive (decreased reflex response), normal, and hyperactive (increased reflex response). Reflexes will be assessed on the treated side in patients undergoing unilateral RFN and bilaterally in patients undergoing bilateral RFN. |
Baseline, 1 month, 3 months, 6 months, and 12 months
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
General Publications
- Cohen SP, Raja SN. Pathogenesis, diagnosis, and treatment of lumbar zygapophysial (facet) joint pain. Anesthesiology. 2007 Mar;106(3):591-614. doi: 10.1097/00000542-200703000-00024.
- Hlaing SS, Puntumetakul R, Khine EE, Boucaut R. Effects of core stabilization exercise and strengthening exercise on proprioception, balance, muscle thickness and pain related outcomes in patients with subacute nonspecific low back pain: a randomized controlled trial. BMC Musculoskelet Disord. 2021 Nov 30;22(1):998. doi: 10.1186/s12891-021-04858-6.
- Oswald KAC, Ekengele V, Hoppe S, Streitberger K, Harnik M, Albers CE. Radiofrequency Neurotomy Does Not Cause Fatty Degeneration of the Lumbar Paraspinal Musculature in Patients with Chronic Lumbar Pain-A Retrospective 3D-Computer-Assisted MRI Analysis Using iSix Software. Pain Med. 2023 Jan 4;24(1):25-31. doi: 10.1093/pm/pnac103.
- Almalki FA, Cortes DH. Multifidus Denervation After Radiofrequency Ablation of the Medial Nerve Alters the Biomechanics of the Spine-A Computational Study. J Appl Biomech. 2023 Aug 29;39(6):414-420. doi: 10.1123/jab.2022-0258. Print 2023 Dec 1.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
Other Study ID Numbers
- 1-26-2459
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.